MENU
+Compare
RLAY
Stock ticker: NASDAQ
AS OF
Sep 26 closing price
Price
$5.17
Change
+$0.79 (+18.04%)
Capitalization
891.37M

RLAY Relay Therapeutics Forecast, Technical & Fundamental Analysis

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients... Show more

RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RLAY with price predictions
Sep 26, 2025

RLAY in upward trend: price rose above 50-day moving average on August 22, 2025

RLAY moved above its 50-day moving average on August 22, 2025 date and that indicates a change from a downward trend to an upward trend. In of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 18, 2025. You may want to consider a long position or call options on RLAY as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RLAY just turned positive on August 22, 2025. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on August 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for RLAY moved above the 200-day moving average on September 12, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in of 244 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 162 cases where RLAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RLAY broke above its upper Bollinger Band on September 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.339) is normal, around the industry mean (19.823). P/E Ratio (0.000) is within average values for comparable stocks, (53.778). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.098). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (349.540).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RLAY is expected to report earnings to rise 1.95% to -41 cents per share on November 05

Relay Therapeutics RLAY Stock Earnings Reports
Q3'25
Est.
$-0.42
Q2'25
Beat
by $0.08
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.12
Q3'24
Beat
by $0.14
The last earnings report on August 07 showed earnings per share of -40 cents, beating the estimate of -49 cents. With 4.07M shares outstanding, the current market capitalization sits at 891.37M.
A.I. Advisor
published General Information

General Information

a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
399 Binney Street
Phone
+1 617 370-8837
Employees
323
Web
https://www.relaytx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DSMFX14.710.16
+1.10%
Destinations Small-Mid Cap Equity I
AICRX39.580.38
+0.97%
American Century Discplnd Cor Val R
CDCRX11.880.10
+0.85%
Copeland Dividend Growth Fund Class C
NBNGX26.310.15
+0.57%
Sit Mid Cap Growth
WLGCX25.940.12
+0.46%
Macquarie Large Cap Growth Fund C

RLAY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with NRIX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
+18.04%
NRIX - RLAY
53%
Loosely correlated
+7.20%
BDTX - RLAY
53%
Loosely correlated
+9.32%
IMNM - RLAY
52%
Loosely correlated
+14.13%
BEAM - RLAY
51%
Loosely correlated
-0.52%
RXRX - RLAY
50%
Loosely correlated
+1.94%
More